Skip to main content
BWAY logo

BrainsWay Ltd. (BWAY) Stock: Price, Forecast & Analyst Target

BrainsWay Ltd. (BWAY) — MoonshotScore 86/100 (Exceptional band), calculated Nov 22, 2026. Price $8.48 (-2.86%), as of the Nov 20, 2026 trading session; market cap $333M.

Educational signal · not a buy or sell recommendation · How to read this

$8.48 −$0.25 (-2.86%) Market Cap $333M

BrainsWay Ltd. · BWAY · NASDAQ

BrainsWay Ltd. is a healthcare company specializing in noninvasive neurostimulation treatments for mental health disorders.

Price as of Nov 20, 2026

Key Statistics

86 of 100

MoonshotScore v2 · BrainsWay (BWAY)

Exceptional
Business Quality Elite (88)
Financial Safety Fortress (93)
Valuation Full (44)
Growth Durability Compounding (99)
Momentum Quiet (47)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite quality, a fortress balance sheet and elite growth, but a full valuation. Business Quality: Elite; Financial Safety: Fortress; Valuation: Full; Growth Durability: Compounding; Momentum: Quiet.

  • EPS beat 6 of the last 8 reports
  • Altman Z 4.95 · Piotroski F 7
  • ROE 13.3% · ROA 4.7% · current ratio 2.89

Helping: business quality, balance-sheet strength, durable growth

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for BWAY (53 recorded, newest six shown)
RecordedScoreBand
89Exceptional
89Exceptional
89Exceptional
87Exceptional
87Exceptional
87Exceptional

The score moved from 87 in the stored Nov 21, 2026 snapshot to 86 in the current publication computed Nov 22, 2026 (-1); the largest pillar moves were Valuation -1 and Momentum +1. This current publication is not yet represented in the immutable snapshot archive.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$8.4851.3% below its 5-year high of $17.40 ()
Change on the day-2.86%
52-week range$7.13 – $17.40
Market capitalisation$333M
Price / earnings (trailing)34.68
Shares traded on the day109.5K

Price & events

Other perspectives

Council score for BrainsWay (BWAY): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Strong
Financial Safety Strong
Valuation Neutral
Growth Durability Strong
Momentum Neutral

Legends Council

4 lenses, 4 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Favorable read

Read on: Nov 22, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Moderate
Margin of Safety Fairly Valued
Profit Margin Moderate
Revenue Growth Strong
Debt/Equity Strong
ROE Moderate
Gross Margin Strong

Read on: Nov 20, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

Two of these lenses read this company less favourably than the MoonshotScore does: Englander-style lens and Klarman-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 22, 2026, except a card that shows its own read date.

1 · What is it?

What is BrainsWay (BWAY), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. BrainsWay Ltd. (BWAY) is listed on NASDAQ. It employs 129 people and is led by Hadar Levy. The market values it at $333M.

2 · Latest results

What do the latest results show for BrainsWay (BWAY)?

Short answer · as of

Against analyst estimates the company has EPS beat 6 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$14M$2M$0.04 (diluted)
Q4 FY2025$15M$3M$0.07 (diluted)
Q1 FY2026$16M$2M$0.06 (diluted)
Q2 FY2026$17M$3M$0.07 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for BrainsWay (BWAY)?

Short answer

The MoonshotScore pillars rate business quality, balance-sheet strength, durable growth as strengths. The distress and quality screens read Altman Z 4.95 · Piotroski F 7. Trailing ratios: ROE 13.3% · ROA 4.7% · current ratio 2.89.

4 · What to check next?

What should you watch next at BrainsWay (BWAY)?

Short answer · as of

Current published price targets run low $19.00 · high $20.00 · consensus $19.50 · median $19.50 against a quoted price of $8.48 (as of Nov 20, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does BrainsWay compare with its peers?

Short answer

BrainsWay's score ranks 1st of 6 in the bounded comparison shown, against 5 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
BrainsWay (BWAY) — this page$8.48$333M86
Medtronic plc (MDT) Named competitor$99.94 Nov 20, 2026$128B82 5-pillar Nov 22, 2026
Koninklijke Philips N.V. (PHG) Named competitor$28.61 Nov 20, 2026$28.0B79 5-pillar Nov 22, 2026
Inspira Technologies Oxy B.H.N. Ltd. (QTEX) Same industry, near in market value$1.00 Nov 20, 2026$70.6M45 5-pillar Nov 22, 2026
SHOULDER INNOVATIONS, INC. (SI) Same industry, near in market value$20.15 Nov 20, 2026$422M35 5-pillar Nov 22, 2026
iTonic Holdings Ltd. (ITOC) Same industry, near in market value$1.59 Nov 20, 2026$11.6M29 5-pillar Nov 22, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$19.00 – $20.00
Consensus target
$19.50
Median target
$19.50

Consensus record · Captured .

Measured against a quoted price of $8.48 (as of Nov 20, 2026).

Insider activity

Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Jun 15, 2026

Transactions
2
Identified insiders
2
Purchases
0
Sales
2
Other transactions
0

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held BWAY in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
ARK InvestCathie WoodQ3 20260.01%$1.94MAdded +3.1% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about BrainsWay (BWAY)?

Read these with our analysis →

What Investors Ask About BrainsWay (BWAY)

These answers are editorial: 1 of these 9 answers is drawn from the BWAY research dossier (written Jun 14, 2026 by gpt-4o-mini); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for BWAY?

BWAY carries the MoonshotScore stated above — the Exceptional band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is BWAY a good stock to buy?

Stock Expert AI does not rate BWAY buy, sell or hold. BrainsWay Ltd. carries a MoonshotScore, in the Exceptional band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the BWAY stock price today?

The last price recorded for BrainsWay Ltd. (BWAY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the BWAY price target?

The analyst consensus price target for BrainsWay Ltd. (BWAY), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What does BrainsWay Ltd. do?

BrainsWay Ltd. specializes in developing noninvasive neurostimulation treatments for various mental health disorders. The company's flagship product, the Deep Transcranial Magnetic Stimulation (dTMS) platform, is designed to treat conditions such as depression, PTSD, and chronic pain.

What are the key factors to evaluate for BWAY?

BrainsWay Ltd. (BWAY) holds a MoonshotScore in the high range. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. By expanding its product offerings, BrainsWay can tap into new revenue streams and enhance its market share within the mental health treatment sector. Not financial advice.

How frequently does BWAY data refresh on this page?

BWAY's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven BWAY's recent stock price performance?

BrainsWay Ltd. (BWAY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative technology with proven efficacy in treating mental health disorders. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider BWAY overvalued or undervalued right now?

The trailing P/E of BrainsWay Ltd. (BWAY) is listed under Price & valuation, and the analyst consensus target under Analyst targets & estimates, on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 19 figures on this page — 11 from Financial Modeling Prep (FMP), 6 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.